Phase 1 Trial Shows Promising Results for KRAS Vaccine in Cancer

A recent clinical trial led by the UCLA Health Jonsson Comprehensive Cancer Center has shown promising results for a novel cancer vaccine called ELI-002 2P, which targets KRAS mutations driving pancreatic and colorectal cancers. In this phase 1 trial, 84% of the 25 participants, including 20 with pancreatic cancer and 5 with colorectal cancer, exhibited durable KRAS-specific T-cell responses. These immune responses involved both CD4+ and CD8+ T cells, which persisted over time. The findings suggest that this vaccine may enhance immune responses and help delay cancer recurrence in high-risk patients whose tumors are influenced by KRAS mutations. The ELI-002 2P vaccine marks a significant advancement in cancer treatment, particularly for pancreatic cancer, which has few effective therapies and a high recurrence rate post-treatment.

The study, published in Nature Medicine, reported that after an average follow-up of 19.7 months, the median relapse-free survival was 16.33 months, while the median overall survival reached 28.94 months. These outcomes notably exceed historical averages, especially for patients who developed robust mKRAS-specific T-cell responses, underscoring the vaccine's potential effectiveness in extending survival. In this trial, patients with pancreatic ductal adenocarcinoma or colorectal cancer who had undergone surgery and showed minimal residual disease were enrolled. Each participant received injections of the ELI-002 2P vaccine, which employs specialized amphiphile technology developed by Elicio Therapeutics to transport antigens directly to lymph nodes, thereby activating immune responses more efficiently.

The study found that 84% of patients generated KRAS-specific T cells, with a significant proportion remaining active over time. Additionally, 24% of patients displayed complete clearance of tumor biomarkers, indicating a positive response to the vaccine. The broader implications of this study extend beyond individual patient outcomes. The ELI-002 2P vaccine is an “off-the-shelf” product, meaning it can be administered without personalized modifications for each patient, a process that can often be lengthy and complex. This standardization could lead to more accessible treatment options for patients with KRAS-driven cancers, which account for about 25% of solid tumors and are responsible for approximately 90% of pancreatic and 50% of colorectal cancers.

The encouraging results from this trial provide a hopeful pathway for future cancer therapies. Looking ahead, the research team has completed enrollment for a larger Phase 2 study, which will assess the next-generation version of the vaccine, ELI-002 7P. This iteration aims to target a broader array of KRAS mutations. The study's senior authors include prominent researchers from leading cancer centers, and the research was sponsored by Elicio Therapeutics. The findings from this study may pave the way for new strategies in cancer immunotherapy, potentially transforming treatment approaches for patients with challenging cancer types.